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Glucocorticoids (GCs) are central to the treatment of inflamma-
tory and immune disorders. These steroids, however, profoundly 
impact the skeleton, particularly when administered for prolonged 
periods. In fact, high-dose GC therapy is almost universally associ-
ated with bone loss, causing one of the most crippling forms of 
osteoporosis. Despite the frequency and severity of GC-induced 
osteoporosis, its treatment is less than satisfactory, suggesting 
that its pathogenesis is incompletely understood.
Net bone mass represents the relative activities of osteoblasts 
and osteoclasts, and there is little question that GCs suppress 
bone-forming cells, in vivo, via a process involving accelerated 
apoptosis (1, 2). In keeping with these in vivo observations, GCs 
blunt expression of molecules such as Runx2 and collagen I (3), 
which mediate osteoblast differentiation and function, respec-
tively. Similarly, these steroids prompt marrow mesenchymal cells 
to express adipocytic genes (4). Surprisingly, however, addition of 
GCs to cultures of osteoprogenitor cells actually increases their 
capacity to form mineralized bone nodules (5, 6). This paradox 
raises the possibility that GC suppression of bone formation in 
vivo reflects, at least in part, targeting of the steroid to intermedi-
ary cells, which in turn inhibit the osteoblast.
Bone remodeling is an ever-occurring event characterized by 
sequential tethering of the activities of osteoclasts and osteoblasts. 
In fact, the majority of acquired, systemic diseases of the skeleton 
reflect imbalance between osteoclast and osteoblast activity in the 
remodeling process. Remodeling units are initiated by the appearance 
of osteoclasts that degrade a packet of bone approximately 50 μm 
deep. These resorptive cells are replaced, at the same location, by 
osteoblast precursors, which synthesize new bone. The osteoporo-
sis attending menopause or GC therapy reflects failure of osteo-
blasts to fully restore bone previously resorbed in remodeling 
sites. This process establishes that osteoclastic bone resorption, in 
some manner, promotes osteoblastic bone formation at the same 
location. Similarly, pathologically or pharmacologically inhibited 
resorption eventuates in arrested osteoblast activity (7, 8).
Bone resorption reflects the sum of osteoclast recruitment and 
death and the rate at which the average cell degrades matrix, each 
of which is controversial regarding GC therapy, as the drugs are 
variously perceived to suppress (9) or enhance (10) generation of 
these cells. In particular, there is little evidence that the steroids 
impact the resorptive machinery of the mature polykaryon.
Osteoclasts are members of the monocyte/macrophage family 
that differentiate under the influence of 2 requisite cytokines, 
namely M-CSF and receptor activator of NF-κB ligand (RANKL) 
(11). RANKL is a member of the TNF superfamily, physiologically 
expressed by osteoblasts and their precursors as a transmembrane 
protein that recognizes its receptor, RANK, on osteoclast lineage 
cells at various states of differentiation. GCs, which arrest osteo-
blast differentiation, also stimulate RANKL (12) and M-CSF (13) 
expression, which, in conjunction with the steroid’s antiapoptotic 
effects on the mature cell (14), would seemingly increase bone-deg-
radative activity. It is therefore curious that there is little evidence 
that accelerated bone resorption contributes to the osteoporosis 
complicating prolonged GC therapy (15). In fact, the histologi-
cal appearance of bones of patients so treated indicates that bone 
resorption as well as formation is suppressed (1, 16, 17).
On the other hand, the conundrum of GC-inhibited bone resorp-
tion, in the face of stimulated RANKL and M-CSF expression and 
prolonged osteoclast lifespan, may reflect direct suppression by 
the steroid of the cell’s resorptive machinery. We find, in fact, 
that while GCs do delay osteoclast apoptosis, they retard the cell’s 
capacity to resorb bone, in vitro and in vivo, by disrupting its cyto-
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skeleton. These effects are GC receptor (GR) mediated and specifi-
cally reflect blockade of M-CSF–stimulated cytoskeletal organiza-
tion. Most importantly, the arrested resorption induced by GCs 
translates to dampened osteoblast activity, as mice in which the 
GR has been conditionally deleted in osteoclast lineage cells are 
protected from steroid-induced bone loss. Thus, suppression of 
the resorptive phase of remodeling contributes to the retarded 
bone formation central to GC-induced osteoporosis.
Results
Dexamethasone exerts variable effects during osteoclast differentiation. 
To define the effects of GCs on osteoclast precursor proliferation 
and survival of the mature resorptive polykaryon, we assessed the 
impact of dexamethasone (DEX) on cells derived from WT mice 
and those with conditional disruption of the GR in a macro-
phage-specific manner (GRoc–/– mice) (18). Validating this model, 
immunoblot analysis using GR-specific antibody showed that GR 
immunoreactivity is undetectable in lysates of GRoc–/– bone mar-
row macrophages (BMMs) and mature osteoclasts (Supplemental 
Figure 1; supplemental material available online with this article; 
doi:10.1172/JCI28084DS1).
Turning to the effects of GCs during different phases of osteo-
clast differentiation, we found that 10 or 100 nM DEX dose-
dependently inhibits WT BMM proliferation while having no 
effect on GRoc–/– cells (Figure 1A). Interestingly, culture of WT 
BMMs in M-CSF and RANKL for 3 days, at which time the cells 
were committed to the osteoclast phenotype, completely abrogated 
the steroid’s antiproliferative effects (Figure 1B). Next, WT BMMs 
were incubated with M-CSF alone or with the osteoclastogenic 
cytokines RANKL, TNF-α, or IL-1α. Like RANKL, TNF-α, but 
not IL-1α, blocks the inhibitory effect of DEX on M-CSF–induced 
BMM proliferation (Figure 1C).
Having explored the impact of GCs on osteoclast precursor pro-
liferation, we turned to apoptosis of the mature, nonreplicating 
cell. Thus, at selected times, DEX was added to 5-day osteoclasto-
genic cultures consisting of BMMs in M-CSF and RANKL. Specifi-
cally, the steroid was present for the entire culture period (5 d) or 
added for the last 2 days or the final 24 hours. Assessment after 
5 days, at which time naive cultures contained sheets of mature 
osteoclasts, established that DEX arrests apoptosis following 
exposure to the steroid as early as 1 day (Figure 1D). These results 
demonstrate that while DEX blunts BMM proliferation, it does 
not affect cells undergoing osteoclast differentiation for as few as 
3 days and protects against apoptosis of mature osteoclasts.
DEX alters osteoclast spreading but not differentiation. We next asked 
whether GCs impact osteoclast differentiation. To this end, we 
assessed the steroid’s effect on expression of 3 osteoclastic genes in 
WT and GRoc–/– BMMs exposed to RANKL and M-CSF for 5 days. 
Neither tartrate-resistant acid phosphatase (TRAP), MMP-9, nor cathep-
sin K mRNAs were present in naive BMMs, but each was induced 
indistinguishably in WT and GRoc–/– cells as they underwent osteo-
clastogenesis in the presence or absence of DEX (Figure 2A). Thus, 
neither GCs nor the GR regulate osteoclast differentiation. On the 
other hand, the steroid had profound effects on osteoclast spread-
ing. DEX, in concentrations as high as 100 nM, did not affect the 
appearance of osteoclasts lacking the GR. In contrast, inhibition of 
WT osteoclast spreading was profound at 1 nM of the steroid and 
universal at 100 nM (Figure 2, B and C). To determine the stage 
of osteoclast differentiation at which GCs inhibit spreading, we 
added DEX, for various periods, to osteoclastogenic cultures initi-
ated with WT or GRoc–/– BMMs (Figure 3A). Attesting to a direct 
effect on the mature osteoclast, exposure to the steroid during the 
last day of osteoclast differentiation was necessary and sufficient 
to arrest spreading (Figure 3B). Thus, DEX inhibits spreading of 
the mature osteoclast and its capacity to resorb mineralized matrix 
and does so independently of cell maturation.
DEX specifically inhibits M-CSF–induced actin organization. The mor-
phological impact of DEX on WT osteoclasts, in the face of normal 
differentiation, suggests the steroid may alter actin organization. 
To determine whether such is the case, we assessed formation of 
Figure 1
DEX impacts osteoclast lineage cells in a dif-
ferentiation- and cytokine-dependent man-
ner. WT and GRoc–/– BMMs were cultured with 
M-CSF (50 ng/ml) in the absence (A) or pres-
ence (B) of RANKL (30 ng/ml) with various 
concentrations of DEX. After 3 days, prolifera-
tion was assessed by BrdU incorporation. (C) 
WT BMMs were incubated with or without DEX 
(100 nM) in the presence of M-CSF alone or 
with RANKL, TNF-α (10 ng/m) or IL-1α (10 ng/
ml) for 3 days. Proliferation was evaluated by 
BrdU incorporation assay. (D) WT and GRoc–/– 
BMMs were cultured with M-CSF and RANKL 
for 5 days to generate mature osteoclasts. DEX 
(100 nM) or vehicle was added for the entire 
5-day culture period or the last 2 days (L2) or 
1 day (L1). After 5 days, the relative apopto-
sis rate was determined by ELISA. *P < 0.01, 
**P < 0.001 within each group.
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the actin ring, a cytoskeletal structure essential for optimal osteo-
clastic bone resorption (11). To this end, mature osteoclasts were 
generated on dentin. Control cells were maintained in M-CSF and 
RANKL, while others were exposed to cold PBS for 5 minutes. The 
cells were then stained with rhodamine-phalloidin to visualize the 
actin cytoskeleton. As seen in Figure 4A, all osteoclasts maintained 
consistently in M-CSF and RANKL exhibited characteristic actin 
rings, which disappeared following treatment with cold PBS. Fur-
thermore, incubation of the PBS-exposed cells in cytokine-free 
medium for 5 hours failed to restore their actin rings.
M-CSF, RANKL, TNF-α, and IL-1α induce actin ring formation 
in mature osteoclasts (19, 20). Thus, we asked whether GCs regu-
late cytoskeletal organization in these cells in a cytokine-specific 
manner. WT and GRoc–/– osteoclasts were plated on dentin and 
cultured in osteoclast-generating medium for 5 days. After wash-
ing with cold PBS to disrupt actin rings, the resorptive polykary-
ons were incubated for 5 hours with various cytokines, with or 
without DEX. Each cytokine, in the absence of DEX, significantly 
restored actin ring formation, an event mirrored by GRoc–/– osteo-
clasts exposed to the steroid (Figure 4, B–F). While DEX did not 
alter RANKL-, TNF-α–, or IL-1α–stimulated actin ring formation 
in WT osteoclasts (Figure 4, C–F), the steroid blocked M-CSF–
induced actin ring formation by 73% (Figure 4, B and F).
DEX arrests M-CSF–stimulated intracellular signaling. Because GCs 
specifically blunt M-CSF–induced cytoskeletal organization in 
osteoclasts, we turned to the signal transduction pathway mediating 
this event. As seen in Supplemental Figure 2, M-CSF strongly acti-
vated ERK1/2 and modestly induced Akt in committed osteoclast 
precursors, but DEX failed to impact either signaling molecule.
Cytoskeletal organization in the osteoclast is regulated by the 
small GTPases RhoA (21) and Rac (22). We therefore assessed RhoA 
activation in M-CSF–treated WT committed preosteoclasts using a 
glutathione-S-transferase (GST) pull-down assay. While RhoA activ-
ity was enhanced approximately 5-fold within 5 minutes exposure 
to the cytokine, DEX completely blocked the induction (Figure 5A). 
Similarly, M-CSF rapidly activated Rac 2.5-fold above control, and 
this was, again, entirely abrogated by DEX (Figure 5B).
Vav3 is an osteoclast-specific guanidine nucleotide exchange fac-
tor that targets Rac. Like RhoA and Rac, Vav3 is essential for osteo-
clast cytoskeletal organization (23). Consistent with its effect on 
Rac, DEX fully arrested the 5-fold increase in Vav3 tyrosine phos-
phorylation induced by M-CSF (Figure 5C). Hence, in keeping with 
its morphological and functional effects, DEX blunts a major cyto-
skeleton-organizing signaling pathway in osteoclasts. We also find 
that DEX-mediated suppression of M-CSF–activated Vav3 required 
16 hours’ exposure to the steroid, indicating that the event is likely 
to be genomic rather than nongenomic (Supplemental Figure 3).
DEX inhibits osteoclastic bone resorption in vitro and in vivo. To deter-
mine the functional implications of GC inhibition of M-CSF– 
induced cytoskeletal organization in the mature osteoclast, we 
assessed the capacity of steroid-treated cells to resorb mineral-
ized matrix. First, BMMs were cultured on dentin slices in M-CSF 
and RANKL, with or without 100 nM DEX, for the entire 5 days 
required to maximize the number of mature osteoclasts. As shown 
in Figure 6A, DEX markedly decreased resorption lacuna forma-
tion by WT but not GRoc–/– cells. Because this result may reflect 
diminished osteoclast number due to suppressed BMM prolif-
eration, we turned to cells committed to the osteoclast phenotype 
Figure 2
DEX-treated BMMs differentiate into osteoclasts but fail to spread. (A) WT and GRoc–/– BMMs were cultured with M-CSF and RANKL with or 
without DEX (100 nM). At day 0 and day 5, RNA was extracted, and the expression of osteoclastogenic markers was analyzed by RT-PCR. 
GAPDH served as loading control. (B) WT and GRoc–/– BMMs were cultured with M-CSF and RANKL with or without increasing concentrations 
of DEX. Five-day osteoclastogenic cultures were stained for TRAP activity. Magnification, ×250. (C) Statistical analysis of the number of WT and 
GRoc–/– spread TRAP-positive multinucleated cells/well. *P < 0.001, **P < 0.0001 versus DEX-untreated WT.
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whose proliferative capacity was no longer impacted by the steroid 
(Figure 6B). To this end, BMMs were maintained on plastic for 2 
days in M-CSF and RANKL. They were then lifted and equal num-
bers cultured on dentin in the presence or absence of DEX for 3 
days. Once again, the steroid arrested resorptive pit formation by 
WT osteoclasts, while those lacking the GR receptor were spared.
Having established that GCs impair osteoclast function in vitro, 
we asked whether the same obtains in vivo. Hence, we treated WT 
and GRoc–/– mice with parathyroid hormone1–34 (PTH1–34), which, 
consistent with our in vitro observations, increased osteoclast num-
ber equally in both genotypes, independent of DEX (Figure 7A). 
On the other hand, the in vivo appearance of PTH1–34–induced 
osteoclasts exposed to the steroid was strikingly different from 
that of control. Whereas naive, PTH1–34–stimulated osteoclasts 
were largely juxtaposed to bone, with robust ruffled membrane 
formation, those in mice also receiving DEX typically failed to con-
tact bone and did not develop this resorptive organelle (Figure 7B). 
Confirming that DEX suppresses stimulated bone resorption, the 
GC blunts the capacity of PTH1–34 to enhance serum tartrate-resis-
tant acid phosphatase 5b (TRACP5b) in WT mice while no such 
inhibition occurs in the absence of the GR (Figure 7C). Thus, con-
sistent with disruption of their cytoskeleton, DEX diminishes the 
activity of osteoclasts in vitro and in vivo.
DEX-suppressed bone formation is mediated through osteoclasts. To deter-
mine whether GC suppression of osteoclast function translates 
into arrested bone formation, we administered DEX (10 mg/kg) 
or vehicle to WT and GRoc–/– mice daily for 14 days. Two courses 
of the fluorescent marker calcein were injected at 6-day intervals 
prior to sacrifice, at which time serum was collected.
As expected, DEX suppressed bone formation in WT mice. 
Specifically, the mineral apposition rate, a histomorphometric 
marker of the functional capacity of the average osteoblast, and 
total bone formation rate were reduced approximately two-thirds 
relative to control in DEX-treated WT mice (Figure 8, A–C). 
Moreover, serum levels of osteocalcin (Figure 8D) and alkaline 
phosphatase (Figure 8E), global biomarkers of bone formation, 
were similarly decreased in these animals. In contrast, the steroid 
did not impact either parameter of bone formation in mice whose 
osteoclasts lacked GRs. On the other hand, osteocyte apopto-
sis was indistinguishable in DEX-treated WT and GRoc–/– mice 
(Figure 8F). Thus, DEX mediates its bone-suppressive effects, at 
least in part, indirectly via the osteoclast.
Discussion
In 1990, Udagawa et al. first generated bone fide osteoclasts in 
culture by coculturing marrow macrophages and osteoblast pre-
cursors (24). The discovery that RANKL, produced by osteoblasts 
and their progenitors, is the key osteoclastogenic cytokine estab-
lished that marrow stromal cells are essential for physiological 
osteoclastogenesis (25).
The alternative concept that osteoblast recruitment to sites of 
bone remodeling is mediated by the osteoclast is longer-stand-
ing yet suffers from a paucity of mechanistic insights (26). Two 
general theories of osteoclast regulation of the osteoblast present 
themselves. Specifically, the osteoclast itself may be the source of 
unidentified, osteoblast-trophic molecules. Buttressing this argu-
ment is the fact that certain forms of osteopetrosis, such as c-src 
deficiency, are characterized by abundant, albeit dysfunctional, 
osteoclasts, yet bone formation is accelerated (27). In other itera-
tions of the disease, such as that due to lack of c-Fos, osteoclas-
togenesis is arrested and bone formation dampened (28, 29). An 
equally compelling argument holds that the osteoclast mobilizes 
matrix-residing growth factors, such as TGF-β and IGFs, which, 
in turn, target and activate the osteoblast (30). Regardless of 
mechanism, the sequential tethering of osteoclastic and osteo-
blastic activity has important clinical implications. For example, 
antiresorptive agents, such as bisphosphonates, are attended by 
suppressed bone formation, a phenomenon that may eventuate in 
adynamic bone and its structural consequences (31). Similarly, the 
bone anabolic properties of PTH are diminished when it is admin-
istered with an antiresorptive drug (7, 8).
Figure 3
DEX inhibits spreading in the later stage of osteoclast differentiation. 
WT and GRoc–/– BMMs were cultured for 5 days in M-CSF and RANKL 
and stained for TRAP activity. The cells were treated with DEX (100 nM) 
for the entire 5 days, the first 3 days (F3), the first 4 days, the last 2 
days, or the last day. Control cultures were maintained in the absence 
of DEX for 5 days. (A) Duration of exposure to Dex in days. (B) Osteo-
clastogenic cultures stained for TRAP activity. Magnification, ×250.
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Prolonged GC therapy leads to yet another example of structur-
ally inferior, adynamic bone, indicating that repressed osteoclast 
function may contribute to diminished formation. These observa-
tions are in keeping with the suggestion of Weinstein that steroid-
induced osteoporosis reflects combined inhibition of both the 
osteoblast and osteoclast (1) and indicate that, as in other states 
of adynamic bone, GC-mediated inhibition of osteoclast function 
retards remodeling and, hence, dampens osteogenesis.
The issue as to whether GCs impact osteoclastic bone resorp-
tion has been controversial. The capacity of these steroids to 
suppress intestinal absorption and renal tubular reabsorption of 
calcium is consistent with a scenario of hormonally stimulated 
bone degradation (32). On the other hand, PTH levels are prob-
ably not increased in most GC-treated patients, and their skel-
etal response to PTH-suppressing agents, such as vitamin D, is 
modest (32). Similarly, GCs attenuate production of sex steroids, 
low levels of which, in other circumstances, promote osteoclastic 
bone resorption (33). Hormone replacement therapy, however, 
does not retard GC-induced bone loss (34). Therefore, if GCs 
impact the osteoclast, they are likely to do so directly or within 
the context of locally produced osteoclast-regulating factors 
such as RANKL or M-CSF.
Our studies of the effects of GCs on various phases of osteoclast 
differentiation and function benefited from the availability of 
mice conditionally disrupting the GR in the entire BMM/osteo-
clast lineage, which permitted us to determine whether individual 
biological events are specific and GR mediated. These mutant 
mice appear indistinguishable from WT for at least 2 months, 
indicating that GC-responsive osteoclasts are not required for 
normal skeletal development. Probably reflecting the short dura-
Figure 4
DEX inhibits M-CSF–induced actin ring forma-
tion. WT and GRoc–/– BMMs were plated on dentin 
and cultured with M-CSF (10 ng/ml) and RANKL 
(100 ng/ml). (A) After 5 days, WT cells were fixed 
before (Con), after washing with cold PBS (wash-
ing control [WC]), or after washing and incuba-
tion in α-MEM/10% FBS (media control [MC]) for 
5 hours. The fixed cells were stained with FITC-
phalloidin to visualize actin rings. (B–E) After 5 days 
WT and GRoc–/– cells were washed with cold PBS 
and incubated with or without DEX (100 nM) in the 
presence of M-CSF (25 or 100 ng/ml) (B), RANKL 
(100 ng/ml) (C), TNF-α (10 ng/ml) (D), or IL-1α 
(10 ng/ml) (E). After 5 hours incubation, the fixed 
cells were stained with FITC-phalloidin. (F) The 
percentage of osteoclasts (OCs) with recovered 
actin ring formation with or without DEX and vari-
ous cytokines. *P < 0.001. Magnification, ×250.
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tion of treatment, histomorphometrically measured bone mass of 
WT and GRoc–/– mice, following 14 days of steroid exposure, was 
similar (data not shown).
We found that DEX regulates osteoclast precursor prolifera-
tion but does so in a differentiation-dependent manner. Thus, 
uncommitted BMMs or those stimulated only by M-CSF to 
develop into mature non-osteoclastogenic macrophages, under-
went divisional arrest in the presence of DEX. IL-1α, which 
alone is not osteoclastogenic (35), also failed to prevent DEX-
suppressed BMM proliferation. In contrast, when the cells were 
maintained in osteoclastogenic medium containing M-CSF 
plus RANKL or TNF-α, the steroid no longer dampened prolif-
eration. Thus, commitment to the bone-resorptive phenotype 
protects macrophages from the antiproliferative effects of GCs. 
Failure of DEX to suppress RANKL-treated osteoclast precur-
sors was mirrored by unaltered activation of ERKs, which medi-
ates replication of the cell.
Weinstein et al. report that GCs prevent apoptosis of the mature 
osteoclast (14), which we confirm. The steroid’s antiapoptotic prop-
erties are not attended by Akt activation, indicating that an alterna-
tive survival pathway is extant. We also note that the antiapoptotic 
effect requires only short exposure to the steroid in the latter phase 
of osteoclast differentiation. Despite their prolonged longevity, 
however, GC-treated osteoclasts have markedly suppressed bone-
resorptive activity in vitro and in vivo. GCs induce RANKL and 
M-CSF expression and blunt synthesis of the osteoclast-inhibitory 
molecule osteoprotegerin (12, 13). These observations, taken with 
the normal proliferation of DEX-treated BMMs committed to the 
osteoclast phenotype, and the drug’s antiapoptotic effect on the 
fully differentiated polykaryon, suggest the steroid would accelerate 
bone resorption in vivo. We found, however, that while the number 
of osteoclasts in PTH-stimulated WT mice treated with DEX mir-
rors the number in those that have not received the steroid, their 
global bone-resorptive activity is suppressed in a GR-mediated 
fashion. This paradox of suppressed bone resorption in the face of 
unaltered osteoclast number indicates that the stimulatory effects 
of GCs on osteoclast survival are obviated by direct inhibition of 
the differentiated cell’s capacity to degrade bone.
The osteoclast is characterized by a unique cytoskeleton, which 
undergoes continuous reorganization with different phases of 
the resorptive cycle (11). We find that DEX, in low nanomolar 
concentrations, disarranges the osteoclast cytoskeleton, yield-
ing cells that fail to spread and ineffectively resorb mineralized 
matrix. Such features are characteristic of a variety of resorptive 
disorders, such as absence of the cytoskeleton-regulating pro-
teins, c-src (13), or the αvβ3 integrin (36). These in vitro GC-
Figure 5
DEX inhibits M-CSF–induced RhoA, Rac, and Vav3 activation. WT BMMs maintained in M-CSF and RANKL for 3 days were exposed to DEX 
(100 nM) or vehicle for 16 hours and then stimulated with M-CSF (100 ng/ml). GTP-RhoA and GTP-Rac were isolated by GST pull-down and 
immunoblotted with RhoA- (A) or Rac-specific (B) antibodies. (C) Vav3 was immunoprecipitated from the cell lysate and phosphotyrosine (p-Tyr) 
content of the immunoprecipitate determined by immunoblot with anti-phosphotyrosine antibody. In all circumstances, the data are expressed 
as fold difference in DEX-exposed (+) relative to vehicle-exposed (–) cells.
Figure 6
DEX suppresses osteoclastic bone resorption in vitro. (A) WT and 
GRoc–/– BMMs were cultured on dentin with RANKL and M-CSF 
with or without DEX. After 5 days, resorption pits were stained with 
toluidine blue (arrows). (B) WT and GRoc–/– BMMs were cultured on 
plastic in the presence of M-CSF and RANKL. After 3 days the cells 
were lifted and replated on dentin in M-CSF and RANKL with or with-
out DEX. Three days later, resorption pits were stained with toluidine 
blue. Magnification, ×100.
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induced events are reflected in vivo by small, irregular osteoclasts 
that fail to attach to or normally degrade bone and lack the cell’s 
key resorptive organelle, its ruffled membrane.
Skeletal degradation occurs in an acidified microenvironment 
between the osteoclast and the bone surface that is isolated from 
the general extracellular space by an actin ring (11). Insufficient 
actin ring generation, in a number of circumstances, is accom-
panied by failure of the osteoclast to spread or adequately resorb 
bone. We describe what we believe to be a novel and rapid assay for 
actin ring formation in osteoclasts under the influence of indi-
vidual cytokines. Interestingly, DEX did not alter the capacity of 
RANKL, TNF-α, or IL-1α to establish actin rings in committed 
osteoclast precursors but substantially suppressed that stimulated 
by M-CSF. While M-CSF is classically viewed as a survival and pro-
Figure 7
DEX suppresses PTH-stimulated bone resorption in vivo. WT and GRoc–/– mice were injected daily for 4 days with vehicle (Con) or PTH or PTH 
plus DEX (n = 4). Histological sections of calvariae were stained for TRAP activity. (A) Osteoclast number/unit bone volume. (B) TRAP-stained 
histological sections of calvariae (arrows indicate osteoclasts with ruffled membranes in resorption lacunae). Magnification, ×250. (C) Serum 
TRACP5b levels at sacrifice. *P < 0.01 versus PTH-treated WT.
Figure 8
GRoc–/– mice are protected from DEX-suppressed bone formation. WT and GRoc–/– mice were injected with DEX (10 mg/kg) or vehicle daily 
for 14 days. Calcein was administered 8 and 2 days prior to sacrifice. (A) Fluorescent micrographs of representative calcein labels. Mag-
nification, ×100. (B) Measured mineral apposition rate. (C) Measured bone formation rate. (D) Serum osteocalcin levels at sacrifice. (E) 
Serum alkaline phosphatase (ALP) levels at sacrifice. (F) Percentage of osteocytes in histological sections of bone undergoing apoptosis. 
*P < 0.05, **P < 0.005 versus control.
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liferative cytokine for osteoclast precursors, it also exerts cytoskel-
etal effects via a signaling pathway shared by the αvβ3 integrin 
(37). Thus, the spreading defect of αvβ3 integrin–deficient osteo-
clasts is rescued by high-dose M-CSF.
The osteoclast cytoskeleton is modulated by a series of small 
GTPases including RhoA (38) and Rac (23) that transit to their 
GTP bond state under the influence of guanine nucleotide 
exchange factors (GEFs). RhoA and Rac are activated in the osteo-
clast by αvβ3 integrin occupancy or M-CSF, both of which induce 
the cell-specific GEF isoform Vav3 (23). Inhibition of RhoA activ-
ity or genetic deletion of Rac (22) or Vav3 (23) arrests osteoclastic 
bone resorption, and we found that DEX prevents M-CSF–mediat-
ed induction of the 3 entities. Hence, GCs suppressed bone resorp-
tion by disrupting the cytoskeleton of the mature resorptive cell in 
an M-CSF/Vav3/RhoA/Rac-dependent manner.
GCs impact cells by genomic and nongenomic mechanisms. 
The steroid’s nongenomic effects occur within seconds to min-
utes and are mediated by the GR or by other means such as G 
protein–coupled receptors (39). Because DEX-mediated suppres-
sion of Vav3 activation requires 16 hours, a genomic locus of 
action is likely. Whether this genomic effect involves direct DNA 
binding of the GR or represents GR associating with an inter-
mediary DNA-interacting protein remains to be determined. In 
any event, our findings provide what we believe to be a novel 
paradigm for the pathogenesis of a common and often devas-
tating form of osteoporosis that to date has remained largely 
refractory to therapeutic intervention.
Methods
Mice. The loxP-floxed GR allele has been described previously (18). Mice used 
for these studies were progeny of lysMCre+loxPhomo × loxPhomo matings. The 
lysM Cre+ knockin was an F1 cross of 129 × C57, as was the loxP allele (40). 
To avoid background drift effects of F2 matings, several breeding pairs were 
analyzed and Cre– littermates were always used as controls for the Cre+ mice 
from the same parents. All mice were 6–10 weeks old and maintained at the 
Animal Facility of Washington University School of Medicine. The Animal 
Ethics Committee of Washington University approved all experiments.
Serum TRACP5b activity. Serum TRACP5b activity was measured by ELISA 
(Immunodiagnostic Systems), after groups of 4 animals were subcutane-
ously injected with 10 μg PTH (human fragment 1–34; Bachem) diluted in 
25 μl of vehicle (1 mM HCl plus 0.1% bovine serum albumin) or PTH plus 
DEX (10 mg/kg) once a day for 4 days. Vehicle alone served as control.
Osteoclast cultures. BMMs were prepared from whole bone marrow of 
6- to 10-week-old mice as described previously (14) and cultured with-
out or with DEX in the presence of GST-RANKL (30 ng/ml) and M-CSF 
(50 ng/ml) in α-MEM containing 10% charcoal-stripped FBS. The medium 
was exchanged every 2 days. Cells were fixed and stained for TRAP activity 
after 5 days. To determine actin ring formation, BMMs were cultured on 
dentin with GST-RANKL (100 ng/ml) and M-CSF (10 ng/ml). After 5 days, 
some cells were fixed and stained with FITC-phalloidin.
Proliferation. Proliferation was determined using the Cell Proliferation 
ELISA system (Amersham Biosciences). After 3 days, BrdU was added to 
each well, and cells were incubated for an additional 4 hours. BrdU incor-
poration was detected following the manufacturer’s instructions.
Osteoclast apoptosis. Osteoclast apoptosis was assessed by ELISA (Cell 
Death Detection ELISA; Roche Diagnostics).
Osteocyte apoptosis. Osteocyte apoptosis was identified in bone sections 
by in situ nick-end labeling using the Klenow terminal deoxynucleotidyl 
transferase (EMD Biosciences) (2).
RT-PCR.Total RNA (1 μg) extracted from cultured cells was used as a 
template for cDNA synthesis. Primers were synthesized on the basis of 
the reported mouse cDNA sequence. The following primers were used: 
for TRAP, 5′-ACAGCCCCCCACTCCCACCCT-3′ and 3′-TCAGGGTCT-
GGGTCTCCTTGG-5′; for MMP-9, 5′-CCTGTGTGTTCCCGTTCATCT-
3′  and 3′-CGCTGGAATGATCTAAGCCCA-5′ ; for cathepsin K, 
5′-GGAAGAAGACTCACCAGAAGC-3′ and 3′-GCTATATAGCCGCCTC-
CACAG-5′; for GAPDH, 5′-ACTTTGTCAAGCTCATTTCC-3′ and 3′-
TGCAGCGAACTTTATTGATG-5′. Amplification was conducted for 
22–30 cycles, each of 94°C for 1 minute, 58°C for 1 minute, and 72°C for 
1 minute. Ten microliters of each reaction mixture was analyzed by 1.5% 
agarose gel electrophoresis.
Cell signaling. mAbs obtained from Cell Signaling Technology were used 
to detect phosphorylated Akt and ERK by immunoblot assay. To assess 
Vav3 activation, cell lysates were immunoprecipitated with polyclonal anti-
body against Vav3 (Upstate USA Inc.), followed by Western blotting using 
anti-phosphotyrosine mAb (4G10; Upstate USA Inc.). Active Rho and Rac 
were measured using Rho and Rac1 Activation Kits (Pierce), following the 
manufacturer’s protocol.
Serum osteocalcin. Serum osteocalcin levels were measured by ELISA 
(Biomedical Technologies Inc.).
Serum alkaline phosphatase. Serum alkaline phosphatase activity was assayed 
using QuantiChrom Alkaline Phosphatase Assay Kit (BioAssay Systems).
Mineral apposition rate and bone formation rate. Mice were administered fluo-
rescent calcein dye (20 mg/kg) 8 and 2 days prior to sacrifice. Non-decalcified 
histological sections of calvariae were prepared and kinetic parameters deter-
mined by fluorescent microscopy using OsteoMeasure (Osteometrics).
Statistics. Data are presented as mean ± SD. Statistical significance was 
determined by 2-tailed Student’s t test. P values less than 0.05 were consid-
ered statistically significant.
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